Anticancer Agent “TASFYGO Tablets 35mg” (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Most cancers with FGFR2 Gene Fusion or Rearrangements By Investing.com
TOKYO, Nov 20, 2024 - (JCN Newswire) - - Eisai Co., Ltd.…
Search
Have an existing account?
Sign In
